论文部分内容阅读
目的对阿托伐他汀在改善高血压合并高血脂患者血管内皮功能中的应用进行相关探讨。方法在高血压合并高血脂患者中随机抽取60例,分为阿托伐他汀10mg组与20mg组,睡前服用阿托伐他汀,治疗时间为12周。抽取50例健康人群为对照组与之进行对比,对三组研究对象的降钙素基因、内皮素、一氧化氮、血脂血压等进行检查对比。结果经数据显示,阿托伐他汀组在治疗前血脂血压要比对照组明显较高,治疗后血脂血压明显下降(P<0.01),阿托伐他汀10mg与20mg组对比,20mg组对高血压患者的血脂改善程度更高。在治疗前,阿托伐他汀组的ET与对照组相比显然要高,CGRP与NO则显著低于对照组,治疗后阿托伐他汀组ET明显下降,CGRP与NO则明显上升(P<0.01),阿托伐他汀10mg组与20mg组相比,20mg组对高血压患者的血管内皮功能改善程度更高。结论阿托伐他汀对高血压合并高血脂患者在改善血管内皮功能方面具有很好的作用,同时还含有剂量依赖性,值得注意。
Objective To investigate the application of atorvastatin in improving the vascular endothelial function in hypertensive patients with hyperlipidemia. Methods Sixty patients were randomized into two groups: atorvastatin 10 mg and 20 mg, and atorvastatin at bedtime. The treatment time was 12 weeks. Fifty healthy subjects were selected as the control group to compare with the control group. The levels of calcitonin gene, endothelin, nitric oxide, blood lipid and blood pressure in the three groups were compared. Results The data showed that before treatment, the blood lipid and blood pressure in atorvastatin group was significantly higher than that in control group, the blood lipid and blood pressure decreased significantly after treatment (P <0.01), atorvastatin 10mg and 20mg group compared with 20mg group The patient’s lipids improve more. Before treatment, ET in atorvastatin group was obviously higher than that in control group, and CGRP and NO were significantly lower than those in control group. ET in atorvastatin group decreased significantly and CGRP and NO increased significantly (P < 0.01), atorvastatin 10mg group compared with 20mg group, 20mg group of hypertension patients with vascular endothelial function improved to a higher degree. Conclusions Atorvastatin has a good effect on improving vascular endothelial function in hypertensive patients with hyperlipidemia, and at the same time it is also dose-dependent.